Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

Coherus Oncology (CHRS) Long-Term Debt Issuances (2016 - 2024)

Coherus Oncology (CHRS) has disclosed Long-Term Debt Issuances for 6 consecutive years, with -$141000.0 as the latest value for Q3 2024.

  • Quarterly Long-Term Debt Issuances changed N/A to -$141000.0 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $49.3 million through Dec 2024, changed N/A year-over-year, with the annual reading at $37.0 million for FY2024, N/A changed from the prior year.
  • Long-Term Debt Issuances hit -$141000.0 in Q3 2024 for Coherus Oncology, down from $49.5 million in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $222.2 million in Q1 2021 to a low of -$674000.0 in Q3 2020.
  • Historically, Long-Term Debt Issuances has averaged $77.1 million across 4 years, with a median of $25.1 million in 2020.
  • Biggest YoY gain for Long-Term Debt Issuances was 240.54% in 2020; the steepest drop was 535.85% in 2020.
  • Year by year, Long-Term Debt Issuances stood at -$674000.0 in 2020, then soared by 33067.36% to $222.2 million in 2021, then crashed by 77.73% to $49.5 million in 2022, then crashed by 100.28% to -$141000.0 in 2024.
  • Business Quant data shows Long-Term Debt Issuances for CHRS at -$141000.0 in Q3 2024, $49.5 million in Q3 2022, and $191.2 million in Q1 2022.